GlassScriptPhysician profile
William H Wilson
NPI 1063587061
$344,426.16
in general payments reported to CMS, 2019-2025
58 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $41K · 2021: $37K · 2022: $51K · 2023: $48K · 2024: $45K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Food and Beverage: $23K · Travel and Lodging: $14K · Honoraria: $9,900 · Consulting Fee: $3,615 · Education: $483 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,836.00 |
| Food and Beverage | $23,357.40 |
| Travel and Lodging | $14,431.07 |
| Honoraria | $9,900.00 |
| Consulting Fee | $3,615.00 |
| Education | $482.96 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93,612.04 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $47,811.58 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Horizon Therapeutics Plc | $40,168.15 | 2019-2023 | Krystexxa |
| Amgen INC. | $40,088.94 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Glaxosmithkline, LLC. | $39,020.31 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $27,842.81 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $16,028.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12,945.13 | 2021-2025 | Saphnelo, Evusheld |
| Pfizer INC. | $7,913.38 | 2019-2025 | |
| Ucb, INC. | $4,776.22 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $3,327.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,126.96 | 2019-2025 | Orencia |
| Genzyme Corporation | $1,065.97 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $1,039.51 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $1,025.96 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $885.30 | 2019-2025 | Taltz, Zepbound |
| Sanofi-Aventis U.S. LLC | $638.81 | 2019-2021 | |
| Genentech USA, INC. | $435.17 | 2019-2025 | Gazyva |
| Radius Health, INC. | $427.10 | 2019-2025 | Tymlos |
| Sobi, INC | $370.03 | 2019-2025 | |
| Celgene Corporation | $366.20 | 2019 | |
| Alexion Pharmaceuticals, INC. | $358.10 | 2019-2025 | Strensiq, Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.87 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| United Therapeutics Corporation | $265.37 | 2023 | Tyvaso |
| Galt Pharmaceuticals, LLC | $243.82 | 2023 | Orphengesic Forte |
| Janssen Scientific Affairs, LLC | $242.67 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $207.78 | 2023-2025 | Horizant, Horizant |
| Medexus Pharma, INC. | $178.44 | 2019-2020 | |
| Organon LLC | $165.92 | 2022-2025 | Renflexis, Hadlima |
| Idorsia Pharmaceuticals US INC | $125.18 | 2022-2023 | Quviviq |
| Intrafusion Gp, LLC | $111.45 | 2021 | |
| Biodelivery Sciences International, INC. | $100.10 | 2019 | |
| Sandoz INC. | $91.84 | 2023-2024 | Hyrimoz |
| Hikma Pharmaceuticals USA | $86.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.04 | 2024-2025 | Hyqvia, Cuvitru |
| Invivyd INC | $82.01 | 2025 | Pemgarda |
| Zyla Life Sciences, INC. | $80.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $78.00 | 2025 | Tremfya |
| Ibsa Pharma INC. | $74.34 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $60.37 | 2024-2025 | Opsumit, Uptravi |
| Antares Pharma, INC. | $55.94 | 2019-2020 | |
| Fidia Pharma USA INC. | $54.04 | 2019-2020 | |
| Tersera Therapeutics LLC | $51.03 | 2024 | Quzyttir |
| Eisai INC. | $45.11 | 2021 | |
| Scilex Pharmaceuticals INC. | $38.31 | 2024 | |
| Mylan Institutional INC. | $37.40 | 2023 | Hulio |
| Assertio Therapeutics, INC. | $34.59 | 2019 | |
| Merck Sharp & Dohme LLC | $33.50 | 2020-2022 | |
| Octapharma USA, INC. | $30.10 | 2023-2024 | Octagam Immune Globulin (Human) |
| Depuy Synthes Sales INC. | $29.89 | 2022 | |
| Tg Therapeutics, INC. | $26.93 | 2023 | |
| Recordati_rare_diseases_inc. | $24.96 | 2023 | Sylvant |
| Alkermes, INC. | $24.40 | 2019 | |
| Bioventus LLC | $23.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.98 | 2023 | Truxima |
| Gilead Sciences, INC. | $14.26 | 2019 | |
| Redhill Biopharma INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.